Surrozen (SRZN) Expected to Release Earnings on Friday

Surrozen (NASDAQ:SRZN) is expected to be releasing its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect the company to announce earnings of ($1.1039) per share and revenue of $0.47 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Surrozen (NASDAQ:SRZN) last released its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.88. The business had revenue of $5.00 million during the quarter, compared to analyst estimates of $0.47 million. On average, analysts expect Surrozen to post ($1.01) EPS for the current fiscal year and ($4.19) EPS for the next fiscal year.

Surrozen Price Performance

SRZN stock opened at $31.65 on Thursday. Surrozen has a twelve month low of $11.39 and a twelve month high of $37.83. The business’s 50-day simple moving average is $24.70 and its 200 day simple moving average is $25.13.

Analyst Ratings Changes

SRZN has been the subject of a number of research reports. William Blair assumed coverage on Surrozen in a research report on Thursday, August 20th. They issued an “outperform” rating and a $51.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research report on Thursday, October 15th. HC Wainwright restated a “buy” rating and issued a $54.00 target price (up from $44.00) on shares of Surrozen in a research note on Friday, September 25th. Finally, Zacks Research raised Surrozen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $48.33.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation.

The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues.